靶向二代测序胚胎植入前非整倍体检测平台偶然检出的小拷贝数变异的确认与致病性
回顾性观察研究纳入2020至2022年12157例接受靶向二代测序PGT-A的患者,评估小CNV偶然发现的技术准确性、遗传来源和致病性。75例(0.62%)符合报告标准,65对夫妇的染色体微阵列随访证实全部病例的配子提供者携带相同CNV,其中母源34例、父源31例,26个(40%)为良性/可能良性,30个(46.2%)为意义不明变异,9个(13.8%)为致病/可能致病。
要点
- 靶向二代测序PGT-A平台可偶然检出小CNV,发生率0.62%(95%CI 0.5%-0.8%)。
- 所有65例获随访的病例均确认配子提供者携带与胚胎一致的CNV(100.0%,95%CI 94.5-100)。
- 检出的CNV中良性/可能良性占40%,意义不明变异占46.2%,致病/可能致病占13.8%。
核心结论
- 某些PGT-A平台可在不预先知晓父母状态的情况下,以极高特异性检出遗传性小CNV。
- 本数据集中大多数CNV被确认为良性/可能良性或意义不明变异。
- 与广泛表型特征相关的致病/可能致病CNV也可能被检出,但当前PGT-A技术对小CNV的可靠阴性预测值因诸多技术挑战尚不可知。
研究设计与样本
- 回顾性观察研究,于2020年至2022年在诊所进行。
- 共纳入12157例接受靶向二代测序临床PGT-A检测全染色体和大片段非整倍体的患者。
- 偶然发现的报告标准为:同一体外受精周期中至少2个胚胎出现至少连续3个扩增子的CNV获得/丢失。
主要发现
- 75例(0.62%;95%CI 0.5%-0.8%)共12157例独特PGT-A患者中检出符合报告标准的偶然发现。
- 所有病例均要求染色体微阵列随访,收到65对生殖夫妇中1方或双方的检测结果。
- 全部病例中,1方配子提供者被确认携带胚胎中检出的CNV(100.0%,N=65/65;95%CI 94.5-100)。
- CNV来源为母源34例(52.3%),父源31例(47.7%)。
- PGT-A预测的CNV大小与染色体微阵列检测大小显著相关(r=0.81),且与亲本DNA上的基因组坐标显著相关。
局限性
- 当前PGT-A技术对小CNV的可靠阴性预测值因诸多技术挑战尚不可知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the technical accuracy, inheritance, and pathogenicity of small copy number variants (CNVs) detected by a targeted next-generation sequencing-based preimplantation genetic testing for aneuploidy (PGT-A) platform. DESIGN: Retrospective observational study performed between 2020 and 2022. SETTING: Clinic. PATIENT(S): A total of 12,157 patients who underwent clinical PGT-A performed by targeted next-generation sequencing for whole chromosome and large segmental aneuploidies. INTERVENTION(S): An incidental finding was reported when a CNV gain/loss of at least 3 consecutive amplicons appeared in at least 2 embryos from the same in vitro fertilization cycle. MAIN OUTCOME MEASURE(S): The primary outcome measures were the specificity, incidence, inheritance, and pathogenicity of small CNVs detected by the PGT-A platform. Accuracy of the PGT-A platform CNV calls was assessed via concordance with the CNV calls (size and genomic location) on chromosomal microarray of the gamete provider(s). Parental origin of the CNV and pathogenicity classifications were also reported. RESULT(S): An incidental finding that met reporting criteria was identified in 75 (0.62%; 95% confidence interval, 0.5%-0.8%) of 12,157 unique PGT-A patients. Chromosomal microarray follow-up was requested for all cases, and results were received for 1 or both members of 65 reproductive couples. In all cases, 1 of the gamete providers was confirmed to have the CNV identified in the embryos (100.0%, N = 65/65; 95% confidence interval, 94.5-100). The identified CNV was of maternal origin in 34 cases (52.3%) and of paternal origin in 31 cases (47.7%). A significant correlation was identified between PGT-A-predicted CNV sizes and chromosomal microarray detected sizes (r = 0.81) and genomic coordinates on parental deoxyribonucleic acid. Twenty-six (40%) of the CNVs were classified as benign/likely benign, 30 (46.2%) as a variant of uncertain significance, and 9 (13.8%) as pathogenic/likely pathogenic. CONCLUSION(S): Certain PGT-A platforms may enable the detection of inherited, small CNVs with extremely high specificity without prior knowledge of parental status. Most CNVs in this data set were confirmed to be benign/likely benign or a variant of uncertain significance. Pathogenic/likely pathogenic CNVs associated with a broad range of phenotypic features may also be detected, although a reliable negative predictive value for small CNVs with current PGT-A technologies is unknown because of the many technical challenges.
引用
- Iturriaga A, Mounts E, Picchetta L, et al. Confirmation and pathogenicity of small copy number variations incidentally detected via a targeted next-generation sequencing-based preimplantation genetic testing for aneuploidy platform. Fertil Steril. 2024. PMID: 38996904. doi:10.1016/j.fertnstert.2024.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。